Renaissance Technologies’s Karyopharm Therapeutics KPTI Stock Holding History

Renaissance Technologies’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$587K	Buy	105,414 +45,500	+76%	+$347K	﹤0.01%	2533
2025 Q4	$441K	Sell	59,914 -4,800	-7%	-$29.4K	﹤0.01%	2624
2025 Q3	$423K	Sell	64,714 -1,100	-2%	-$5.92K	﹤0.01%	2863
2025 Q2	$284K	Buy	65,814 +4,600	+8%	+$22.6K	﹤0.01%	3061
2025 Q1	$229K	Sell	61,214 -18,959	-24%	-$162K	﹤0.01%	3040
2024 Q4	$813K	Sell	80,173 -2,587	-3%	-$31.3K	﹤0.01%	2601
2024 Q3	$1.03M	Buy	82,760 +32,345	+64%	+$402K	﹤0.01%	2429
2024 Q2	$656K	Sell	50,415 -10,038	-17%	-$166K	﹤0.01%	2554
2024 Q1	$1.37M	Sell	60,453 -70,505	-54%	-$1.24M	﹤0.01%	2278
2023 Q4	$1.7M	Buy	130,958 +82,265	+169%	+$1.11M	﹤0.01%	2052
2023 Q3	$979K	Buy	48,693 +4,200	+9%	+$94.3K	﹤0.01%	2315
2023 Q2	$1.2M	Sell	44,493 -4,554	-9%	-$196K	﹤0.01%	2361
2023 Q1	$2.86M	Buy	49,047 +36,427	+289%	+$1.8M	﹤0.01%	1800
2022 Q4	$644K	Sell	12,620 -7,933	-39%	-$550K	﹤0.01%	2795
2022 Q3	$1.68M	Sell	20,553 -9,767	-32%	-$730K	﹤0.01%	2133
2022 Q2	$2.05M	Buy	30,320 +15,980	+111%	+$1.47M	﹤0.01%	2170
2022 Q1	$1.58M	Buy	14,340 +8,613	+150%	+$1.07M	﹤0.01%	2410
2021 Q4	$552K	Sell	5,727 -27,300	-83%	-$2.72M	﹤0.01%	3029
2021 Q3	$2.88M	Buy	33,027 +31,796	+2,583%	+$3.3M	﹤0.01%	1813
2021 Q2	$191K	Buy	+1,231	New	+$179K	﹤0.01%	3256
2020 Q3	–	Sell	-12,120	Closed	-$3.44M	–	3531
2020 Q2	$3.44M	Sell	12,120 -23,480	-66%	-$6.94M	﹤0.01%	1854
2020 Q1	$10.3M	Buy	35,600 +24,900	+233%	+$6.87M	0.01%	1145
2019 Q4	$3.08M	Buy	+10,700	New	+$2.32M	﹤0.01%	2112
2019 Q3	–	Sell	-4,901	Closed	-$440K	–	3571
2019 Q2	$440K	Sell	4,901 -56,352	-92%	-$4.52M	﹤0.01%	3043
2019 Q1	$5.37M	Buy	61,253 +32,836	+116%	+$3.64M	﹤0.01%	1761
2018 Q4	$3.99M	Buy	28,417 +23,704	+503%	+$4M	﹤0.01%	1861
2018 Q3	$1.2M	Sell	4,713 -4,480	-49%	-$1.24M	﹤0.01%	2529
2018 Q2	$2.34M	Buy	+9,193	New	+$2.27M	﹤0.01%	2187

Other funds holding KPTI

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Renaissance Technologies's KPTI Position: Q1 2026 in Review

Renaissance Technologies increased its Karyopharm Therapeutics (KPTI) stake by 76% in Q1 2026, buying an estimated $347K and bringing the position to 105,414 shares worth $587K. The position accounts for ﹤0.01% of the portfolio, ranked #2533.

Renaissance Technologies first reported a position in KPTI in Q2 2018 and has held it in 28 quarters since. The position peaked at $10.3M in Q1 2020. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

Renaissance Technologies held 105,414 shares of Karyopharm Therapeutics worth $587K as of Q1 2026.
Renaissance Technologies bought 45,500 Karyopharm Therapeutics shares in Q1 2026, an estimated $347K.
Karyopharm Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #2533 holding.
Renaissance Technologies first reported a position in Karyopharm Therapeutics in Q2 2018 and has held it in 28 quarters since.
Renaissance Technologies's Karyopharm Therapeutics position peaked at $10.3M in Q1 2020.
77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.